InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $2.110 -0.51 (-19.47%)+
Announcement
Release
5 Aug 2026 10:00AM
Price at Release
$2.620
Full Release
download
Summary
Clarity Pharmaceuticals Ltd has provided an update on its SECuRE trial, a Phase I/IIa study focusing on the use of 67Cu-SAR-bisPSMA in treating prostate cancer. The trial, currently in its Cohort Expansion Phase, examines the efficacy and safety of the 8 GBq dose level, with significant results such as 74% of participants achieving a reduction in PSA levels of 25% or more, and 31% achieving complete response or undetectable disease. The study involves patients with metastatic castration-resistant prostate cancer who have undergone multiple prior treatments. The safety profile of the treatment appears favorable, with mostly mild to moderate adverse events. These promising outcomes support ongoing enrollment and future Phase III planning.
Key Points
  • SECuRE trial focuses on 67Cu-SAR-bisPSMA for prostate cancer.
  • Significant PSA reductions observed in participants.
  • 31% of participants achieved complete response or undetectable disease.
  • Favorable safety profile with mild to moderate adverse events.
  • Ongoing enrollment in Cohort Expansion Phase.
  • Plans for Phase III trial based on current data.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.